Active, not recruitingPhase 2NCT04291885

Immunotherapy Adjuvant Trial in Patients With Stage I-III Merkel Cell Carcinoma

Studying Cutaneous neuroendocrine carcinoma

Last synced from ClinicalTrials.gov May 7, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Melanoma and Skin Cancer Trials Limited
Principal Investigator: A/Prof Wen Xu, MBBS, FRACP
Princess Alexandra Hospital
Intervention: Avelumab(drug)
Enrollment: 122 enrolled
Eligibility: 18 years · All sexes
Timeline: 2020 – 2030

Study locations (20)

Port Macquarie Base Hospital, Port Macquarie, New South Wales, Australia
Chris O'Brien Lifehouse, Sydney, New South Wales, Australia
Melanoma Institute Australia, Sydney, New South Wales, Australia
Royal North Shore Hospital, Sydney, New South Wales, Australia
Westmead Hospital, Sydney, New South Wales, Australia
Calvary Mater Hospital, Sydney, New South Wales, Australia
Cancer Care Wollongong, Wollongong, New South Wales, Australia
Royal Brisbane and Woman's Hospital, Brisbane, Queensland, Australia
Cancer Care Service, Bundaberg Base Hospital, Bundaberg, Queensland, Australia
Cairns Hospital, Cairns, Queensland, Australia
Cancer Care Service, Hervey Bay Hospital, Hervey Bay, Queensland, Australia
Mackay Hospital and Health Service, Mackay, Queensland, Australia
Tasman Health Care, Southport, Queensland, Australia
Townsville Hospital, Townsville, Queensland, Australia
Princess Alexandra Hospital, Woolloongabba, Queensland, Australia
+5 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04291885 on ClinicalTrials.gov

Other trials for Cutaneous neuroendocrine carcinoma

Additional recruiting or active studies for the same condition.

See all trials for Cutaneous neuroendocrine carcinoma →

← Back to all trials